Placebo News and Research

RSS

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

A new study by UCLA researchers has found that Naltrexone, a drug used to treat alcoholism, may also be a promising treatment for addiction to methamphetamine.

19 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

Short course of oral steroids unlikely to provide much benefit for patients with acute sciatica

Among patients with acute sciatica caused by a herniated lumbar disk (a condition also known as "acute radiculopathy"), a short course of oral steroids resulted in only modest improvement in function and no significant improvement in pain, according to a study published today in the Journal of the American Medical Association.

19 May 2015

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant efficacy in treating opioid-induced constipation (OIC) in patients with chronic non-cancer pain.

19 May 2015

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease.

19 May 2015

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility.

19 May 2015

Two-drug combination improves lung function in some cystic fibrosis patients

The combination of two drugs — an investigational drug used in conjunction with an already FDA-approved medication — improved lung function in patients with one form of cystic fibrosis, according to two new studies.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Live, multi-strain probiotic drink may benefit people with ulcerative colitis

People with ulcerative colitis may benefit from taking the live, multi-strain probiotic drink, Symprove, to reduce intestinal inflammation, according to the results of a new study presented today at Digestive Disease Week 2015.

18 May 2015

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference.

18 May 2015

Combined therapy shows promise in cystic fibrosis patients

Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase III international clinical trial published online in the New England Journal of Medicine on May 17, 2015.

17 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery...

15 May 2015

Drug combination lengthens lives of metastatic colorectal cancer patients

A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

15 May 2015

Exposure to secondhand cannabis smoke causes mild intoxication

Researchers recruited seven people ages 18 to 45 who said they smoked cannabis at least twice per week and tested positive for THC, but who tested negative for other drugs, and 12 others in the same age range who said they had not used cannabis in the past six months and tested negative for cannabis, other drugs, and alcohol...

14 May 2015

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.

14 May 2015

Secondhand exposure to cannabis smoke under extreme conditions impairs cognitive performance

Secondhand exposure to cannabis smoke under "extreme conditions," such as an unventilated room or enclosed vehicle, can cause nonsmokers to feel the effects of the drug, have minor problems with memory and coordination, and in some cases test positive for the drug in a urinalysis.

14 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015.

13 May 2015

New landmark study to examine role of cocoa flavanols in maintaining cardiovascular health

Recognizing that heart health is one of the world's most significant public health challenges, Mars, Incorporated, in collaboration with Brigham and Women's Hospital (BWH), a teaching affiliate of Harvard Medical School, is launching a five-year landmark study to examine the role of cocoa flavanols, plant-derived bioactives from the cacao bean, in helping people maintain cardiovascular health.

12 May 2015

Placebo News and Research

No added benefit with pazopanib over ranibizumab for neovascular AMD

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Short course of oral steroids unlikely to provide much benefit for patients with acute sciatica

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Two-drug combination improves lung function in some cystic fibrosis patients

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Live, multi-strain probiotic drink may benefit people with ulcerative colitis

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

Combined therapy shows promise in cystic fibrosis patients

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

Drug combination lengthens lives of metastatic colorectal cancer patients

Exposure to secondhand cannabis smoke causes mild intoxication

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

Secondhand exposure to cannabis smoke under extreme conditions impairs cognitive performance

Galmed reports net loss of $2.5 million for first quarter 2015

New landmark study to examine role of cocoa flavanols in maintaining cardiovascular health

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News